| Literature DB >> 32280132 |
Jianhua Zhai1, Anlong Qi1, Yan Zhang1, Lina Jiao1, Yancun Liu1, Songtao Shou1.
Abstract
BACKGROUND This work aimed to screen key biomarkers related to sepsis progression by bioinformatics analyses. MATERIAL AND METHODS The microarray datasets of blood and neutrophils from patients with sepsis or septic shock were downloaded from Gene Expression Omnibus database. Then, differentially expressed genes (DEGs) from 4 groups (sepsis versus normal blood samples; septic shock versus normal blood samples; sepsis neutrophils versus normal controls and septic shock neutrophils versus controls) were respectively identified followed by functional analyses. Subsequently, protein-protein network was constructed, and key functional sub-modules were extracted. Finally, receiver operating characteristic analysis was conducted to evaluate diagnostic values of key genes. RESULTS There were 2082 DEGs between blood samples of sepsis patients and controls, 2079 DEGs between blood samples of septic shock patients and healthy individuals, 6590 DEGs between neutrophils from sepsis and controls, and 1056 DEGs between neutrophils from septic shock patients and normal controls. Functional analysis showed that numerous DEGs were significantly enriched in ribosome-related pathway, cell cycle, and neutrophil activation involved in immune response. In addition, TRIM25 and MYC acted as hub genes in protein-protein interaction (PPI) analyses of DEGs from microarray datasets of blood samples. Moreover, MYC (AUC=0.912) and TRIM25 (AUC=0.843) had great diagnostic values for discriminating septic shock blood samples and normal controls. RNF4 was a hub gene from PPI analyses based on datasets from neutrophils and RNF4 (AUC=0.909) was capable of distinguishing neutrophil samples from septic shock samples and controls. CONCLUSIONS Our findings identified several key genes and pathways related to sepsis development.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32280132 PMCID: PMC7171431 DOI: 10.12659/MSM.920818
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Gene expression datasets for sepsis and septic shock.
| GEO accession | Type | Case | Control | Platform | Author |
|---|---|---|---|---|---|
| GSE69528 | Blood samples (sepsis | 83 | 24 | GPL10558 IlluminaHumanHT-12 V4.0 expression beadchip | Scott Presnell |
| GSE46955 | Blood samples (sepsis | 8 | 6 | GPL6104 IlluminahumanRef-8 v2.0 expression beadchip | Michael Poidinger |
| GSE54514 | Blood samples (sepsis | 127 | 36 | GPL6947 IlluminaHumanHT-12 V3.0 expression beadchip | Grant Parnell |
| GSE32707 | Blood samples (sepsis | 30 | 34 | GPL10558 IlluminaHumanHT-12 V4.0 expression beadchip | Judie Ann Howrylak |
| GSE28750 | Blood samples (sepsis | 10 | 20 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | Gareth Price |
| GSE13015 | Blood samples (sepsis | 29 | 5 | GPL6947 IlluminaHumanHT-12 V3.0 expression beadchip | Damien Chaussabel |
| GSE9960 | Blood samples (sepsis | 54 | 16 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | Benjamin Man Piu Tang |
| GSE33118 | Blood samples (septic shock | 20 | 42 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | Wolfgang Raffelsberger |
| GSE95233 | Blood samples (septic shock | 102 | 22 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | Julien Textoris |
| GSE57065 | Blood samples (septic shock | 82 | 25 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | Marie-Angélique Cazalis |
| GSE49755 | Neutrophil samples (sepsis | 29 | 17 | GPL10558 IlluminaHumanHT-12 V4.0 expression beadchip | Damien Chaussabel |
| GSE49756 | Neutrophil samples (sepsis v controls) | 24 | 12 | GPL10558 IlluminaHumanHT-12 V4.0 expression beadchip | Damien Chaussabel |
| GSE49757 | Neutrophil samples (sepsis | 35 | 19 | GPL10558 IlluminaHumanHT-12 V4.0 expression beadchip | Damien Chaussabel |
| GSE123729 | Neutrophil samples (septic shock | 15 | 11 | GPL21970 [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array | Carsten Sticht |
| GSE64457 | Neutrophil samples (septic shock | 15 | 8 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | Julien Textoris |
GEO – Gene Expression Omnibus.
Figure 1The bidirectional clustering analysis of differentially expressed genes (DEGs). (A) The heatmap of DEGs from blood samples of sepsis and healthy controls. (B) The heatmap of DEGs from blood samples of septic shock and healthy controls. (C) The heatmap of DEGs from neutrophil samples of sepsis and normal controls. (D) The heatmap of DEGs from neutrophil samples of septic shock and normal controls. The “label” shows the type of microarray dataset. Each row and column respectively represent the gene and sample. The blue-green color represents the control samples and the pink color represents the sepsis or septic shock samples.
Figure 2The GO functional annotation of DEGs. (A) The top 10 GO terms enriched by DEGs from blood samples of sepsis and healthy controls in 3 GO categories (GO-BP; GO-CC and GO-MF). (B) The top 10 GO terms enriched by DEGs from blood samples of sepsis and healthy controls in 3 GO categories (GO-BP; GO-CC and GO-MF). (C) The top 10 GO terms enriched by DEGs from neutrophil samples of sepsis and normal controls in 3 GO categories (GO-BP; GO-CC and GO-MF). (D) The top 10 GO terms enriched by DEGs from neutrophil samples of septic shock and normal controls in 3 GO categories. GO – Gene Ontology; DEGs – differentially expressed genes; MF – molecular function; CC – cellular component; BP – biological process.
Figure 3The KEGG pathway enrichment analysis of DEGs. (A) The top 15 KEGG pathways of DEGs from blood samples of sepsis patients and healthy controls. (B) The top 15 KEGG pathways of DEGs from blood samples of sepsis patients and healthy controls. (C) The top 15 KEGG pathways of DEGs from neutrophil samples of sepsis and normal controls. (D) The significant enriched KEGG pathway of DEGs from neutrophil samples of septic shock and normal controls. The color close to red shows a higher significance. KEGG – Kyoto Encyclopedia of Genes and Genomes; DEGs – differentially expressed genes.
Figure 4The functional sub-network analysis of PPI network based on the blood and neutrophil samples from sepsis patients. (A–D) The 4 sub-modules from PPI network of DEGs from blood samples of sepsis and healthy controls. (E, F) The 3 sub-modules from PPI network of DEGs from neutrophil samples of sepsis and healthy controls. The red color nodes represent upregulated genes and the blue nodes show the downregulated genes. PPI – protein–protein interaction; DEGs – 0differentially expressed genes.
Figure 5The functional sub-network analysis of PPI network based on the blood and neutrophil samples from septic shock patients. (A–H) The 8 sub-modules from PPI network of DEGs from blood samples of septic shock and healthy controls. (I) The one sub-module from PPI network of DEGs from neutrophil samples of septic shock and normal controls. The red color nodes represent upregulated genes and the blue nodes show the downregulated genes. PPI – protein–protein interaction; DEGs – differentially expressed genes.
Figure 6ROC curve of 3 differentially expressed genes. The ROC curves to show the diagnostic value of 3 key genes (MYC, TRIM25, and RNF4) in sepsis or septic shock with sensitivity and 1-specificity. The x-axis shows 1-specificity and y-axis represents sensitivity. (A) ROC curve of MYC in sepsis. (B) ROC curve of MYC in septic shock. (C) ROC curve of TRIM25 in septic shock. (D) ROC curve of RNF4 in septic shock. The gene has a great diagnostic value for septic shock when AUC value of this gene >0.8. ROC – receiver operating characteristic; AUC – area under the ROC curve.
The hub genes in the PPI network.
| Group 1 | Group 2 | Group 3 | Group 4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Degree | Type | Gene | Degree | Type | Gene | Degree | Type | Gene | Degree | Type |
| TRIM25 | 329 | Up | KIAA1429 | 1056 | Down | TRIM25 | 313 | Up | RNF4 | 112 | Down |
| MYC | 317 | Down | TRIM25 | 796 | Up | RNF4 | 185 | Down | UBC | 111 | Up |
| APP | 269 | Up | MYC | 713 | Down | COPS5 | 110 | Down | RNF2 | 77 | Down |
| XPO1 | 206 | Down | ELAVL1 | 697 | Down | MEPCE | 91 | Down | SUZ12 | 66 | Down |
| RNF4 | 203 | Down | RECQL4 | 520 | Up | HDAC1 | 89 | Down | CYLD | 60 | Down |
Group 1: the PPI network analysis of DEGs between sepsis and normal controls from blood samples; Group 2: the PPI network analysis of DEGs between septic shock and normal controls from blood samples; Group 3: the PPI network analysis of DEGs between sepsis and normal controls from neutrophil samples; Group 4: the PPI network analysis of DEGs between septic shock and normal controls from neutrophil samples. PPI – protein–protein interaction; DEGs – differentially expressed genes; Up represents the upregulation of the gene and Down represents the downregulation of the gene.
The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes (DEGs) in protein–protein interaction (PPI) sub-modules (top 5).
| Names | Terms | Gene count | Gene symbols | |
|---|---|---|---|---|
| Group1_sub-module 1 | Ribosome | 28 | 2.78E-62 | |
| Thyroid cancer | 1 | 0.025 | ||
| Bladder cancer | 1 | 0.035 | ||
| Endometrial cancer | 1 | 0.044 | ||
| Acute myeloid leukemia | 1 | 0.048 | ||
| Group1_sub-module 2 | RNA transport | 9 | 3.35E-18 | |
| Malaria | 1 | 0.0187 | ||
| B cell receptor signaling pathway | 1 | 0.0276 | ||
| RNA degradation | 1 | 0.0290 | ||
| mRNA surveillance pathway | 1 | 0.0345 | ||
| Group1_sub-module 3 | RNA degradation | 9 | 6.46E-18 | |
| Spliceosome | 5 | 5.37E-08 | ||
| Ribosome biogenesis in eukaryotes | 2 | 0.0020 | ||
| Rap1 signaling pathway | 2 | 0.0105 | ||
| MicroRNAs in cancer | 2 | 0.0202 | ||
| Group1_sub-module 4 | Spliceosome | 3 | 1.11E-05 | |
| RNA degradation | 2 | 0.0003 | ||
| RNA polymerase | 1 | 0.0107 | ||
| Basal transcription factors | 1 | 0.0149 | ||
| Pyrimidine metabolism | 1 | 0.0341 | ||
| Group2_sub-module 1 | – | – | – | |
| Group2_sub-module 2 | Cell cycle | 2 | 0.0128 | |
| MAPK signaling pathway | 4 | 0.0003 | ||
| MicroRNAs in cancer | 4 | 0.0007 | ||
| Viral carcinogenesis | 3 | 0.0029 | ||
| Chronic myeloid leukemia | 2 | 0.0047 | ||
| Group2_sub-module 3 | Spliceosome | 7 | 3.76E-12 | |
| Oocyte meiosis | 2 | 0.0030 | ||
| Cell cycle | 2 | 0.0031 | ||
| Pathogenic Escherichia coli infection | 1 | 0.0360 | ||
| Shigellosis | 1 | 0.0423 | ||
| Group2_sub-module 4 | Spliceosome | 2 | 0.0006 | |
| Ribosome | 2 | 0.0007 | ||
| PI3K-Akt signaling pathway | 2 | 0.0039 | ||
| Intestinal immune network for IgA production | 1 | 0.0140 | ||
| Legionellosis | 1 | 0.0154 | ||
| Group2_sub-module 5 | Cell cycle | 1 | 0.1849 | |
| RNA degradation | 6 | 5.10E-09 | ||
| Spliceosome | 6 | 1.18E-07 | ||
| Proteasome | 4 | 1.19E-06 | ||
| Ribosome | 5 | 3.86E-06 | ||
| Group2_sub-module 6 | Axon guidance | 3 | 0.0005 | |
| Cell cycle | 2 | 0.0055 | ||
| Endocrine resistance | 3 | 9.50E-05 | ||
| PI3K-Akt signaling pathway | 4 | 0.0002 | ||
| Signaling pathways regulating pluripotency of stem cells | 3 | 0.0003C | ||
| Group2_sub-module 7 | DNA replication | 3 | 0.0001 | |
| RNA transport | 6 | 5.79E-06 | ||
| Proteasome | 4 | 6.41E-06 | ||
| Nucleotide excision repair | 4 | 8.18E-06 | ||
| Cell cycle | 1 | 0.2675 | ||
| Group2_sub-module 8 | Cell cycle | 4 | 0.0005 | |
| Metabolic pathways | 19 | 3.30E-09 | ||
| Purine metabolism | 7 | 1.04E-06 | ||
| Pyrimidine metabolism | 5 | 1.68E-05 | ||
| RNA polymerase | 3 | 0.0001 | ||
| Group3_sub-module 1 | Transcriptional misregulation in cancer | 2 | 0.0011 | |
| Nicotinate and nicotinamide metabolism | 1 | 0.0085 | ||
| Acute myeloid leukemia | 1 | 0.0159 | ||
| Fc epsilon RI signaling pathway | 1 | 0.0189 | ||
| Chronic myeloid leukemia | 1 | 0.0203 | ||
| Group3_sub-module 2 | Endocytosis | 4 | 6.04E-07 | |
| Protein processing in endoplasmic reticulum | 3 | 1.21E-05 | ||
| Endocrine and other factor-regulated calcium reabsorption | 2 | 8.12E-05 | ||
| Legionellosis | 2 | 0.0001 | ||
| Synaptic vesicle cycle | 2 | 0.0001 | ||
| Group3_sub-module 3 | Hippo signaling pathway -multiple species | 3 | 9.45E-09 | |
| Hippo signaling pathway | 3 | 1.20E-06 | ||
| Ras signaling pathway | 2 | 0.0004 | ||
| MicroRNAs in cancer | 2 | 0.0008 | ||
| Pathways in cancer | 2 | 0.0015 | ||
| Group4_sub-module | Thyroid hormone signaling pathway | 1 | 0.0149 |
Group 1: the blood samples of sepsis and healthy controls; Group 2: the blood samples of septic shock and healthy controls; Group 3: the neutrophil samples of sepsis and normal controls; Group 4: the neutrophil samples of septic and normal controls.